Out Team
Our Research
STARLIGHT Initiative
Project PRESCIENT
PMAC Catalog

Welcome!

The Cancer Discovery Hub (CDH) is a one-stop pan-omics diagnostic and research core laboratory housed at the National Cancer Centre Singapore. We specialise in state-of-the-art research-grade technologies and provide expert support to investigators on all cancer related projects.

 

Latest news

Key events and achievements

  • 19 Aug 2022 : Invited speech, 6th International BRCA Forum, Singapore

    • Precision Oncology: The Time is Now !

  • 19 Aug 2022 : Collaborative research agreement with Scinnohub Pharmaceutical

  • 19 Aug 2022 : Collaborative research agreement with MGI Tech

  • 04 Aug 2022 : Collaborative research agreement with Twist Bioscience

  • 16 Jun 2022 : Best Oral Presentation, International Congress of the Asian Oncology Society (AOS 2022), South Korea

    • ctDNA mutations in progressive gastrointestinal stromal tumors identify drug resistance biomarkers and uncover potential therapeutic strategies (Tun Kiat KO)

  • 12 Apr 2022 : Invited Oral Presentation at Major Symposium, AACR Annual Meeting, New Orleans

    • Identification and characterization of human angiosarcoma subtypes through multi-omic multi-dimensional profiling

  • 22 Feb 2022 : Publication on circulating tumor DNA mutations in progressive gastrointestinal stromal tumors, Frontiers in Oncology

  • 17 Feb 2022 : Travel Award for Poster abstract at Japanese Society of Medical Oncology Annual Meeting, Japan

    • Dissecting Intratumoral Heterogeneity of Sarcomatoid RCC Arising from Autosomal Dominant Polycystic Kidney Disease (Elizabeth LEE)

  • 15 Feb 2022 : Identification of fibroblasts as key secretors of PAI-I using single cell sequencing, published in Cell Reports Medicine

  • 12 Jan 2022 : Commercial launch of the UNITED NGS Assay (Lucence) for Asian prevalent cancers at the NCCS

  • 21 Oct 2021 : Collaborative research agreement with STEMCELL Technologies

  • 01 Sep 2021 : Collaborative research agreement with SymBio Pharmaceuticals on EBV-positive lymphomas

  • 01 Sep 2021 : Official launch of Cancer Discovery Hub!

 

Start a project consultation with us

Featured Publications

Scientific publications supported by the Cancer Discovery Hub

HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis
BMC Medicine. 2022

Mar, 2022

HER2-low breast cancer (BC) is currently an area of active interest. This study evaluated the impact of low expression of HER2 on survival outcomes in HER2-negative non-metastatic breast cancer (BC). Patients with HER2-negative non-metastatic BC from 6 centres within the Asian Breast Cancer Cooperative Group (ABCCG) (n = 28,280) were analysed. Results: ABCCG cohort median follow-up was 6.6 years; there were 12,260 (43.4%) HER2-low BC and 16,020 (56.6%) HER2-zero BC. The outcomes were better in HER2-low BC than in HER2-zero BC (RFS: centre-adjusted hazard ratio (HR) 0.88, 95% CI 0.82-0.93, P < 0.001; OS: centre-adjusted HR 0.82, 95% CI 0.76-0.89, P < 0.001). On multivariable analysis, HER2-low status was prognostic (RFS: HR 0.90, 95% CI 0.85-0.96, P = 0.002; OS: HR 0.86, 95% CI 0.79-0.93, P < 0.001). These differences remained significant in hormone receptor-positive tumours and for OS in hormone receptor-negative tumours. Superior outcomes were observed for HER2 IHC1+ BC versus HER2-zero BC (RFS: HR 0.89, 95% CI 0.83-0.96, P = 0.001; OS: HR 0.85, 95% CI 0.78-0.93, P = 0.001). Conclusions: HER2-low BC had a superior prognosis compared to HER2-zero BC in the non-metastatic setting, though absolute differences were modest and driven by HER2 IHC 1+ BC. ERBB2 CNV merits further investigation in HER2-negative BC.

Contact us

  • LinkedIn
  • Facebook
  • Instagram

Thanks for submitting!